Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

Healthcare Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

COSCIENS Biopharma Inc > New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2245)
•••
Comment by lscfaon Aug 13, 2024 10:13am
48 Views
Post# 36176400

RE:RE:New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

RE:RE:New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

w-t-h?
 

 

 

Ceapro revenue

Aeterna revenue

Total 

Cosciens

Q2 24

 

 

 

2,337

Q1 24

2,774

4

2,778

2,057

Q4 23

1,651

55

1,706

1,213

Q3 23

2,619

3

2,622

1,952

Q2 23

1,869

2,246

4,115

1,392

Q1 23

3,495

2,128

5,623

2,585

Q4 22

3,322

2,485

5,807

2,447

Q3 22

3,845

1,860

5,705

2,944

 



lscfa wrote: Cooked books.   Last year Aeterna reported Q2 revenue of $2.246M, now it shows it as $1.392M

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities